Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

BACKGROUND: Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of patients with metastases at different visceral site...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Min, Li, Jun‐Jie, Zuo, Wen‐Jia, Ji, Lei, Jiang, Yi‐Zhou, Hu, Xi‐Chun, Wang, Zhong‐Hua, Shao, Zhi‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797565/
https://www.ncbi.nlm.nih.gov/pubmed/31373147
http://dx.doi.org/10.1002/cam4.2453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797565/
https://www.ncbi.nlm.nih.gov/pubmed/31373147
http://dx.doi.org/10.1002/cam4.2453

Ejemplares similares